-
4 weeks ago | 
onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi
• , , , et al., “ CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia ,” Journal of Clinical Oncology , no. ( ): – . • , , , et al., “ The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms ,” Leukemia , no. ( ): – .
-
1 month ago | 
nature.com | Naseema Gangat |Ayalew Tefferi
Momelotinib, a small-molecule Janus kinase 1 and 2 (JAK1/2) and activin A receptor, type 1 (ACVR1)/activin receptor-like kinase 2 (ALK2) inhibitor, represents an important addition to the treatment armamentarium for myelofibrosis (MF), due to its ability to not only address splenomegaly, and constitutional symptoms but also alleviate anemia [1, 2].
-
1 month ago | 
nature.com | Mithun Vinod Shah |Kevin Hung |Anmol Baranwal |Aref Al-Kali |Antoine Saliba |dong chen | +18 more
AbstractThe World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53mut) myeloid neoplasm (MN). However, there are substantial differences between the two classifications that may lead to under- or overestimation of the prognostic risk. We retrospectively applied WHO-5 and ICC to 603 MN cases harboring TP53mut (variant allele frequency, VAF ≥ 2%).
-
2 months ago | 
nature.com | Naseema Gangat |Ayalew Tefferi
Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.
-
Mar 15, 2025 | 
onlinelibrary.wiley.com | Carlo Brugnara |Alessandro Vannucchi |Ayalew Tefferi
• , “ As I Recall the Beginning of the American Journal of Hematology Forty Years Ago ,” American Journal of Hematology ( ): , https://doi.org/10.1002/ajh.24205. • , “ The American Journal of Hematology in 2007 ,” American Journal of Hematology , no. ( ): – , https://doi.org/10.1002/ajh.21160. • and , “ The American Journal of Hematology, 2011 and Beyond ,” American Journal of Hematology , no. ( ): 1, https://doi.org/10.1002/ajh.21951.
-
Mar 9, 2025 | 
onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi
Conflicts of Interest N.G. has served on the Advisory Board for DISC Medicine and Agios. References 1, , , et al., “Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients,” Mayo Clinic Proceedings 90, no. 12 (2015): 1623–1638, https://doi.org/10.1016/j.mayocp.2015.08.022. 2, , , et al., “One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience,” Mayo Clinic Proceedings 87, no. 1 (2012): 25–33.
-
Mar 3, 2025 | 
nature.com | Daniel A. Arber |Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui
AbstractA lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time.
-
Feb 12, 2025 | 
onlinelibrary.wiley.com | Ayalew Tefferi |Naseema Gangat
Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.
-
Dec 27, 2024 | 
onlinelibrary.wiley.com | Patricia Carey |Animesh Pardanani |Patrick Starlinger |Ayalew Tefferi
To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.
-
Dec 13, 2024 | 
onlinelibrary.wiley.com | Ayalew Tefferi |Vincent Ho
• , , , et al., “ Indication and Management of Allogeneic Haematopoietic Stem-Cell Transplantation in Myelofibrosis: Updated Recommendations by the EBMT/ELN International Working Group ,” Lancet Haematology ( ): – . • and , “ 2024 Update on Allogeneic Hematopoietic Stem Cell Transplant for Myelofibrosis: A Review of Current Data and Applications on Risk Stratification and Management ,” American Journal of Hematology ( ): – .
